NaraMyx Health Care’s diagnostics division focuses on multiplex technologies designed for the detection of multiple infectious pathogens.
The diagnostic portfolio described in the business plan covers bacterial, fungal and viral targets associated with urinary tract infections, urogenital infections and invasive pulmonary infections.
Engineered to enable simultaneous multi-pathogen identification with scientific accuracy.
Designed to evaluate multiple pathogen targets within a multiplex testing workflow.
Part of NaraMyx’s broader diagnostic technology portfolio for quantitative biomarker analysis.
Multi-target bacterial and viral evaluation for complex and recurrent urinary infection panels.
Simultaneous detection of prevalent sexually transmitted and urogenital pathogens from a single sample.
Deep respiratory panel targets designed to identify bacterial and fungal co-infections in critical pulmonary presentations.
Syndromic screening workflows intended to assist differential diagnosis across overlapping infectious disease symptoms.
By evaluating multiple targets within a single diagnostic workflow, multiplex testing can provide healthcare professionals with broader information from a single sample.
NaraMyx aims to combine rapid turnaround with accurate pathogen detection to support timely, targeted clinical decision-making in infectious-disease management.
